Research information only, not medical advice. Retatrutide's most commonly reported side effects in clinical trials are gastrointestinal — nausea, vomiting, and diarrhea — generally mild to moderate and easing over time, consistent with the GLP-1 receptor agonist class. Retatrutide is investigational and not approved for human use.
Across the randomized trials indexed on this page, the most frequent adverse events with retatrutide were gastrointestinal and generally mild to moderate, subsiding over time. In a 40-week phase 3, double-blind, placebo-controlled trial in adults with type 2 diabetes (Bajaj et al.), treatment discontinuations due to adverse events were 2-5% with retatrutide versus 0% with placebo, and no severe hypoglycemia was reported. These figures describe what was observed in supervised trials of an investigational drug: retatrutide is not FDA-approved, and this page reports the research rather than giving medical advice.
For the full evidence base, clinical trials, and regulatory status, see the Retatrutide research overview . Related: retatrutide dosage , retatrutide benefits .
Sources
Frequently asked questions
- Does retatrutide cause nausea?
- Nausea is among the gastrointestinal effects reported in retatrutide trials, alongside vomiting and diarrhea. In the indexed studies these events were generally mild to moderate and eased over time.
- Are retatrutide's side effects serious?
- In a phase 3 type 2 diabetes trial, discontinuations due to adverse events were 2-5% and no severe hypoglycemia was reported. Retatrutide remains investigational; this is trial data, not medical advice.
Updated · sourced to primary documents